Rebound with positive rapid home antigen test/Symptoms of sneezing and nasal congestion; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (Rebound with positive rapid home antigen test/Symptoms of sneezing and nasal congestion) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014f21A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension, Coronary artery disease and Allergy (allergy to unspecified drug).    On 25-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-May-2022, the patient experienced COVID-19 (Rebound with positive rapid home antigen test/Symptoms of sneezing and nasal congestion). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 08-May-2022 to 13-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Rebound with positive rapid home antigen test/Symptoms of sneezing and nasal congestion) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-May-2022, SARS-CoV-2 test: positive (Positive) Rebound with positive rapid home antigen test 8 days later.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was unknown.  It was reported that Rebound with positive rapid home antigen test 8 days later. Symptoms of sneezing and nasal congestion developed. Patient did not received any treatment.  company comment: This spontaneous case concerns a 44-year-old male patient, with no reported relevant medical history, who experienced, unexpected, non-serious, AESI of COVID-19, approximately 7 months after receiving mRNA-1273 vaccine as a third dose.  Information with regards to previous doses of COVID-19 vaccines is unavailable in this report.  The patient was treated with Nirmatrelvir-Ritonavir (Paxlovid) for five days at unspecified dose and frequency.  Seven days after completing a course of Paxlovid, the patient reported rebound symptoms and new onset of sneezing and nasal congestion.  The patient underwent SARS-CoV-2 rapid home antigen test which showed positive result.    The outcome of the event was unknown.  The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 44-year-old male patient, with no reported relevant medical history, who experienced, unexpected, non-serious, AESI of COVID-19, approximately 7 months after receiving mRNA-1273 vaccine as a third dose.  Information with regards to previous doses of COVID-19 vaccines is unavailable in this report.  The patient was treated with Nirmatrelvir-Ritonavir (Paxlovid) for five days at unspecified dose and frequency.  Seven days after completing a course of Paxlovid, the patient reported rebound symptoms and new onset of sneezing and nasal congestion.  The patient underwent SARS-CoV-2 rapid home antigen test which showed positive result.    The outcome of the event was unknown.  The benefit-risk relationship of mRNA-1273 is not affected by this report.